Tubocurarine Chloride

CHEMBL3989821 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
681.6 g/mol
LogP
Phase
4

Tubocurarine chloride is the chloride salt of tubocurarine, the prototype non-depolarizing neuromuscular blocking agent that competitively blocks nicotinic receptors at the motor end plate to produce reversible skeletal muscle paralysis. It was used as an anesthetic adjunct for surgical muscle relaxation and to facilitate endotracheal intubation. It has been superseded by agents with shorter duration, more predictable reversal, and fewer adverse effects.

Молекулярная масса

681,6000 g/mol

TPSA

80,60 Ų

Механизм действия

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-]

InChI

InChI=1S/C37H40N2O6.2ClH.5H2O/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33;;;;;;;/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41);2*1H;5*1H2/t28-,29+;;;;;;;/m0......./s1

Molecular Formula

C37H42Cl2N2O6

HBD / HBA

3 / 8

Вращаемые Связи

2

Тяжёлые Атомы

47

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Tubocurarine chloride is the chloride salt of tubocurarine, the prototype non-depolarizing neuromuscular blocking agent that competitively blocks nicotinic receptors at the motor end plate to produce reversible skeletal muscle paralysis. It was used as an anesthetic adjunct for surgical muscle relaxation and to facilitate endotracheal intubation. It has been superseded by agents with shorter duration, more predictable reversal, and fewer adverse effects.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Tubocurarine Chloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989821. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16051918. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.